Answers are grounded in this paper and cite their sources.
Examines treatment de-escalation strategies in inflammatory bowel disease, highlighting clinical decision challenges.
Advances in the management of inflammatory bowel disease have led to earlier use of effective therapies and higher rates of sustained remission. As a consequence, clinicians are increasingly required to consider whether ongoing treatment intensity remains appropriate once disease control is established. As a result, decisions around treatment de-escalation are increasingly encountered in clinical practice requiring a balance between reducing long-term treatment exposure and the risk of relapse. The evidence supporting treatment de-escalation strategies remains variable. Most data derive from studies of anti-tumour necrosis factor therapies while evidence for newer biologics and oral agents is more limited. Relapse rates following treatment withdrawal are substantial and reliable predictors of long-term treatment-free remission are lacking. Decisions must, therefore, integrate disease phenotype, prior disease course, objective markers of inflammatory control and patient preferences alongside an understanding of the limitations of the current evidence base. The evidence supporting treatment de-escalation strategies remains variable. Most data derive from studies of anti-tumour necrosis factor therapies while evidence for newer biologics and oral agents is more limited. Relapse rates following treatment withdrawal are substantial and reliable predictors of long-term treatment-free remission are lacking. Decisions must, therefore, integrate disease phenotype, prior disease course, objective markers of inflammatory control and patient preferences alongside an understanding of the limitations of the current evidence base.
No takes yet. Share an insight, caveat, or question.
M. Swaminathan (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: